Ventricular Assist Device
- Bridge to transplant — It buys time for the heart transplant candidate to wait for a suitable donor while providing the opportunity to gain strength and prevent or alleviate other side effects of severe cardiac failure.
- Destination therapy — It improves quality of life for patients with end-stage heart failure who are not heart transplant candidates.
- Bridge to decision — It buys time to determine whether a patient is a candidate for heart transplant.
- Bridge to recovery — It allows natural cardiac function to improve by providing mechanical assistance.
Houston Methodist's LVAD ExpertiseOur specialists, under the leadership of renowned cardiologist Dr. Michael E. DeBakey, began implanting LVADS in the late 1990s. Since then, we have established a vigorous LVAD treatment and research program, performing an estimated 60 LVAD procedures annually.
Our experts also lead LVAD research, making Houston Methodist the top-enrolling center in a 41-site worldwide initiative. Additionally, Houston Methodist is a leading center in the Momentum 3 trial, studying differences among ventricular assist systems. Our specialists also participate in international consortiums and conferences to better understand advanced heart failure.
Ventricular Assist Device Criteria
- New York Heart Association (NYHA) functional classification III or IV
- Multiple hospitalizations for heart failure
- Inotrope dependence (patient required to take medicine for heart function)
- Intractable (cannot control) arrhythmias
- Intractable (cannot control) angina
- Ejection fraction (EF) less than 30 percent, increasing the risk for cardiac arrest